Jo-Ann S Passmore1, Heather B Jaspan, Lindi Masson. 1. aInstitute of Infectious Diseases and Molecular Medicine, University of Cape Town Medical School, Cape Town bNRF-DST Centre of Excellence in HIV Prevention, Centre for the AIDS Programme of Research, Durban, South Africa cSeattle Children's Hospital, Seattle, Washington, USA dNational Health Laboratory Service, Cape Town, South Africa.
Abstract
PURPOSE OF REVIEW: Women who have genital inflammation are at increased risk of sexual HIV infection. The purpose of this review is to evaluate the mechanisms for this relationship, causes of genital inflammation, and strategies to manage this condition. RECENT FINDINGS: We have recently shown in a cohort of South African women that HIV seroconversion was associated with persistently raised genital inflammatory cytokines (including MIP-1α, MIP-1β, and IP-10). Elevated inflammatory cytokine concentrations may facilitate HIV infection by recruiting and activating HIV target cells and disrupting the mucosal epithelial barrier. Bacterial vaginosis and sexually transmitted infections (STIs), which are predominantly asymptomatic in women, cause lower genital tract inflammation and increased HIV acquisition risk. In Africa, where syndromic management of STIs and bacterial vaginosis is standard-of-care, the substantial burden of asymptomatic infections has likely contributed to high-HIV incidence rates. SUMMARY: A genital inflammatory profile contributes to the high risk of HIV acquisition in African women. STIs and bacterial vaginosis are poorly managed in Africa and other developing nations and as such remain major drivers of persistent genital inflammation and HIV acquisition among these women.
PURPOSE OF REVIEW: Women who have genital inflammation are at increased risk of sexual HIV infection. The purpose of this review is to evaluate the mechanisms for this relationship, causes of genital inflammation, and strategies to manage this condition. RECENT FINDINGS: We have recently shown in a cohort of South African women that HIV seroconversion was associated with persistently raised genital inflammatory cytokines (including MIP-1α, MIP-1β, and IP-10). Elevated inflammatory cytokine concentrations may facilitate HIV infection by recruiting and activating HIV target cells and disrupting the mucosal epithelial barrier. Bacterial vaginosis and sexually transmitted infections (STIs), which are predominantly asymptomatic in women, cause lower genital tract inflammation and increased HIV acquisition risk. In Africa, where syndromic management of STIs and bacterial vaginosis is standard-of-care, the substantial burden of asymptomatic infections has likely contributed to high-HIV incidence rates. SUMMARY: A genital inflammatory profile contributes to the high risk of HIV acquisition in African women. STIs and bacterial vaginosis are poorly managed in Africa and other developing nations and as such remain major drivers of persistent genital inflammation and HIV acquisition among these women.
Authors: Linnet Masese; Jared M Baeten; Barbra A Richardson; Elizabeth Bukusi; Grace John-Stewart; Susan M Graham; Juma Shafi; James Kiarie; Julie Overbaugh; R Scott McClelland Journal: AIDS Date: 2015-06-01 Impact factor: 4.177
Authors: Fransje A Koning; Sigrid A Otto; Mette D Hazenberg; Linda Dekker; Maria Prins; Frank Miedema; Hanneke Schuitemaker Journal: J Immunol Date: 2005-11-01 Impact factor: 5.422
Authors: Janneke H H M van de Wijgert; Charles S Morrison; Peter G A Cornelisse; Marshall Munjoma; Jeanne Moncada; Peter Awio; Jing Wang; Barbara Van der Pol; Tsungai Chipato; Robert A Salata; Nancy S Padian Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: Jia Zhu; Florian Hladik; Amanda Woodward; Alexis Klock; Tao Peng; Christine Johnston; Michael Remington; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey Journal: Nat Med Date: 2009-08-02 Impact factor: 53.440
Authors: Jordan K Kyongo; Vicky Jespers; Odin Goovaerts; Johan Michiels; Joris Menten; Raina N Fichorova; Tania Crucitti; Guido Vanham; Kevin K Ariën Journal: PLoS One Date: 2012-08-31 Impact factor: 3.240
Authors: A C Hearps; D Tyssen; D Srbinovski; L Bayigga; D J D Diaz; M Aldunate; R A Cone; R Gugasyan; D J Anderson; G Tachedjian Journal: Mucosal Immunol Date: 2017-04-12 Impact factor: 7.313
Authors: Lianna F Wood; Bryan P Brown; Katie Lennard; Ulas Karaoz; Enock Havyarimana; Jo-Ann S Passmore; Anneke C Hesseling; Paul T Edlefsen; Louise Kuhn; Nicola Mulder; Eoin L Brodie; Donald L Sodora; Heather B Jaspan Journal: Clin Infect Dis Date: 2018-09-28 Impact factor: 9.079
Authors: R Scott McClelland; Jairam R Lingappa; Sujatha Srinivasan; John Kinuthia; Grace C John-Stewart; Walter Jaoko; Barbra A Richardson; Krista Yuhas; Tina L Fiedler; Kishorchandra N Mandaliya; Matthew M Munch; Nelly R Mugo; Craig R Cohen; Jared M Baeten; Connie Celum; Julie Overbaugh; David N Fredricks Journal: Lancet Infect Dis Date: 2018-01-26 Impact factor: 25.071